SPOTLIGHT: ProStrakan float flounders

The UK's ProStrakan has cut its stock valuation for the fifth time, seeking £40 million. Last May, ProStrakan outlined plans to raise £100 million. A string of European biotechs has suspended plans to go public in recent weeks amid signs of a chilly market response. Release